Erlotinib
Trovati 10 articoli
- Efficacy and safety of Sunitinib in previously treated, advanced non-small cell lung cancer
- A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. “ This is the first clinical trial to evaluate Sunitinib alone in advanced lung cancer patients for who... (Leggi Articolo)
- Advanced lung cancer, Tarceva extends survival
- A study, led by Canadian researchers, has demonstrated that Erlotinib ( Tarceva ) increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options. The trial, funded by the Canadian Cancer Society and published in The New England Journal of... (Leggi Articolo)
- Tarceva in the treatment of advanced or metastatic pancreatic cancer
- Erlotinib ( Tarceva ) is the first drug and the only EGFR-targeted treatment shown to prolong survival in a phase III trial ( PA3 ) when added to standard of care ( Gemcitabine ) for the treatment of patients with previously untreated advanced pancreatic cancer. Tarceva was approved by the FD... (Leggi Articolo)
- Advanced non-small cell lung cancer, Tarceva benefits older patients
- According to Researchers from Dana-Farber Cancer Institute in Boston, Tarceva ( Erlotinib ), a tyrosine kinase inhibitor, showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer ( NSCLC ). " While fur... (Leggi Articolo)
- Tarceva can prolong survival in patients with lung cancer
- A trial, conducted by Canadian researchers, determined whether the epidermal growth factor receptor ( EGFR ) inhibitor Tarceva ( Erlotinib ) prolongs survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. Patients with stage IIIB or IV non–small-ce... (Leggi Articolo)
- Pancreatic tumor: chemotherapy plus Erlotinib improves survival
- A randomized study of Erlotinib ( Tarceva ) plus Gemcitabine met its primary endpoint by demonstrating a statistically significant 23.5 percent improvement in overall survival ( or a hazard ratio of 0.81, which can also be referred to as a 19 percent reduction in the risk of death ) when compared... (Leggi Articolo)
- FDA Advisory Panel recommends Tarceva approval for pancreatic cancer
- The FDA’s Oncologic Drug Advisory Committee ( ODAC ) voted 10 to 3 in favor of recommending approval of Tarceva ( Erlotinib ) in combination with Gemcitabine for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Pancreatic cancer has the high... (Leggi Articolo)
- Tarceva in association with Gemzar for advanced, inoperable or metastatic pancreatic carcinoma, FDA approved
- The FDA ( U.S. Food and Drug Administration ) has approved Tarceva ( Erlotinib ) in combination with Gemcitabine ( Gemzar ) chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva is the first drug in a Phase III trial to ha... (Leggi Articolo)
- Can most types of cancers be prevented ?
- Debate exists on how many cancer deaths are preventable in principle - estimates range from 50 percent to 80 percent - but most researchers agree that tobacco use ( mostly smoking ) accounts for the majority. Today, cigarette smoking claims about 438,000 premature deaths in the U.S. annually. It ... (Leggi Articolo)
- Lung cancer, Tarceva receives positive opinion from CHMP
- Tarceva ( Erlotinib ) has received a positive recommendation from the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of non-small cell lung cancer, the most common form of lung cancer. Tarceva is the first and only EGFR-targeted treatment to have shown a sig... (Leggi Articolo)
